Drugs Approved in 2012
Abraxane (paclitaxel protein-bound particles for injectable suspension); Celgene; For the treatment of non-small cell lung cancer, Approved October 2012
Afinitor (everolimus); Novartis; For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex, Approved April 2012
Afinitor (everolimus); Novartis; For the treatment of hormone receptor-positive, HER2-negative breast cancer, Approved July 2012
Bosulif (bosutinib); Pfizer; For the treatment of Ph+ chronic myelogenous leukemia, Approved September 2012
Cometriq (cabozantinib); Exelixis; For the treatment of metastatic medullary thyroid cancer, Approved November 2012
Erivedge (vismodegib); Genentech; For the treatment of basal cell carcinoma, Approved January 2012
Iclusig (ponatinib); Ariad Pharmaceuticals; For the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, Approved December 2012
Inlyta (axitinib); Pfizer; For the treatment of advanced renal cell carcinoma, Approved January 2012
Kyprolis (carfilzomib); Onyx Pharmaceuticals; For the treatment of multiple myeloma, Approved July 2012
Marqibo (vinCRIStine sulfate LIPOSOME injection); Talon Therapeutics; For the treatment of Ph- acute lymphoblastic leukemia, Approved August 2012
Neutroval (tbo-filgrastim); Teva Pharmaceutical; For the reduction in the duration of severe chemotherapy-induced neutropenia, Approved August 2012
Perjeta (pertuzumab); Genentech; For the first-line treatment of HER2+ metastatic breast cancer, Approved June 2012
Picato (ingenol mebutate) gel; LEO Pharma; For the treatment of actinic keratosis, Approved January 2012
Stivarga (regorafenib); Bayer HealthCare Pharmaceuticals; For the treatment of previously treated patients with metastatic colorectal cancer, Approved September 2012
Subsys (fentanyl sublingual spray); Insys Therapeutics; For the treatment of breakthrough cancer pain, Approved January of 2012
Synribo (omacetaxine mepesuccinate); Teva Pharmaceutical; For the treatment of chronic or accelerated phase chronic myeloid leukemia, Approved October 2012
Votrient (pazopanib); GlaxoSmithKline; For the treatment of soft tissue sarcoma, Approved April 2012
Xtandi (enzalutamide); Medivation; For the treatment of metastatic castration-resistant prostate cancer, Approved August 2012
Zaltrap (ziv-aflibercept); Sanofi-aventis; For the treatment of metastatic colorectal cancer, Approved August 2012
Drugs Approved in 2011
Abstral (fentanyl sublingual tablets); ProStrakan; For the treatment of breakthrough cancer pain in opioid-tolerant patients, Approved January 2011
Adcetris (brentuximab vedotin); Seattle Genetics; For the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma, Approved August 2011
Afinitor (everolimus); Novartis; For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011
Erwinaze (asparaginase Erwinia chrysanthemi); Eusa Pharma; For the treatment of acute lymphoblastic leukemia, Approved November of 2011
Lazanda (fentanyl citrate) nasal spray; Archimedes; For the management of breakthrough cancer pain, Approved June 2011
Sutent (sunitinib malate); Pfizer; For the treatment of pancreatic neuroendocrine tumors, Approved May 2011
Sylatron (peginterferon alfa-2b); Merck; For the treatment of melanoma, Approved April 2011
Vandetanib (vandetanib); AstraZeneca; For the treatment of thyroid cancer, Approved April 2011
Xalkori (crizotinib); Pfizer; For the treatment of ALK+ non-small cell lung cancer, Approved August of 2011
Yervoy (ipilimumab); Bristol-Myers Squibb; For the treatment of metastatic melanoma, Approved March 2011
Zelboraf (vemurafenib); Roche; For the treatment of BRAF + melanoma, Approved August of 2011
Zytiga (abiraterone acetate); Centocor Ortho Biotech; For the treatment of prostate cancer, Approved May 2011
Drugs Approved in 2010
Halaven (eribulin mesylate); Eisai; For the treatment of metastatic breast cancer, Approved November 2010
Herceptin (trastuzumab); Genentech; For the treatment of gastric cancer, Approved October 2010
Jevtana (cabazitaxel); sanofi aventis; For the treatment of prostate cancer, Approved June 2010
Provenge (sipuleucel-T); Dendreon; For the treatment of hormone refractory prostate cancer, Approved May 2010
Xgeva (denosumab); Amgen; For the prevention of skeletal-related events in patients with bone metastases from solid tumors, Approved November 2010
Zuplenz (ondansetron oral soluble film); Strativa Pharmaceuticals; For the prevention of post-operative, chemotherapy and radiotherapy induced nausea and vomiting, Approved July 2010
Drugs Approved in 2009
Afinitor (everolimus); Novartis; For the treatment of renal cell carcinoma, Approved March 2009
Arzerra (ofatumumab); GlaxoSmithKline; For the treatment of chronic lymphocytic leukemia, Approved October 2009
Avastin (bevacizumab); Genentech; For the treatment of renal cell carcinoma, Approved July 2009
Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant; GlaxoSmithKline; For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18, Approved October 2009
Elitek (rasburicase); sanofi-aventis; For the management of plasma uric acid levels in adults with malignancies, Approved October 2009
Folotyn (pralatrexate injection); Allos Therapeutics; For the treatment of peripheral T-cell lymphoma, Approved September 2009
Istodax (romidepsin); Gloucester Pharmaceuticals; For the treatment of cutaneous T-cell lymphoma, Approved November 2009
Onsolis (fentanyl buccal); BioDelivery Sciences; For the management of breakthrough cancer pain, Approved July 2009
Votrient (pazopanib); GlaxoSmithKline; For the treatment of renal cell carcinoma, Approved October of 2009
Drugs Approved in 2008
Degarelix (degarelix for injection); Ferring Pharmaceuticals; For the treatment of prostate cancer, Approved December of 2008
Fusilev (levoleucovorin); Spectrum Pharmaceuticals; For rescue after high-dose methotrexate therapy in osteosarcoma and to reduce the toxicity of methotrexate, Approved March of 2008
Mozobil (plerixafor injection); Genzyme; For the treatment of non-Hodgkin’s lymphoma and multiple myeloma, Approved December 2008
Sancuso (granisetron); ProStrakan; For the treatment of chemotherapy-induced nausea and vomiting, Approved September 2008
Treanda (bendamustine hydrochloride); Cephalon; For the treatment of Chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma, Approved October 2008
Drugs Approved in 2007
Evista (raloxifene hydrochloride); Eli Lilly; For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007
Hycamtin (topotecan hydrochloride); GlaxoSmithKline; For the treatment of small cell lung cancer, Approved October 2007
Ixempra (ixabepilone); Bristol-Myers Squibb; For the treatment of breast cancer, Approved October 2007
Tasigna (nilotinib hydrochloride monohydrate); Novartis; For the treatment of chronic myelogenous leukemia, Approved October 2007
Torisel (temsirolimus); Wyeth; For the treatment of renal cell carcinoma, Approved May 2007
Tykerb (lapatinib); GlaxoSmithKline; For the treatment of breast cancer, Approved March 2007
Drugs Approved in 2006
Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine); Merck; For the prevention of cervical cancer associated with human papillomavirus, Approved June 2006
Sprycel (dasatinib); Bristol-Myers Squibb; For the treatment of imatinib-resistant chronic myeloid leukemia, Approved June 2006
Sutent (sunitinib); Pfizer; For the treatment of kidney cancer and gastrointestinal stromal tumors, Approved January 2006
Vectibix (panitumumab); Amgen; For the treatment of colorectal cancer, Approved September 2006
Drugs Approved in 2005
Arranon (nelarabine); GlaxoSmithKline; For the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, Approved October 2005
Nexavar (sorafenib); Bayer/Onyx; For the Treatment of Renal Cell Carcinoma, Approved December 2005
Drugs Approved in 2004
Alimta (pemetrexed for injection); Eli Lilly; For the treatment of malignant pleural mesothelioma, Approved February 2004
Avastin (bevacizumab); Genentech; For the treatment of metastatic carcinoma of the colon or rectum, Approved February 2004
Clolar (clofarabine); Genzyme; For the treatment of acute lymphoblastic leukemia in pediatric patients, Approved December, 2004
Erbitux (cetuximab); Imclone, Bristol-Myers Squibb; For the treatment of EGFR-expressing, metastatic colorectal cancer, Approved February 2004
Sensipar (cinacalcet); Amgen; For the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients, Approved March 2004
Tarceva (erlotinib, OSI 774); Genentech, OSI Pharmaceuticals; For the treatment of advanced refractory metastatic non-small cell lung cancer, Approved November, 2004
Drugs Approved in 2003
Aloxi (palonosetron); MGI Pharma, Helsinn Healthcare; For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, Approved August 2003
Bexxar; Corixa; For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse, Approved June 2003
Emend (aprepitant); Merck; For the treatment of nausea and vomiting associated with chemotherapy, Approved March 2003
Iressa (gefitinib); AstraZeneca; For the second-line treatment of non-small-cell lung cancer, Approved May 2003
Plenaxis (abarelix for injectable suspension); Praecis Pharmaceuticals; For treatment of advanced prostate cancer, Approved December 2003
Premarin (conjugated estrogens); Wyeth; For the prevention of postmenopausal osteoporosis and treatment of vasomotor menopause symptoms, Approved July of 2003
UroXatral (alfuzosin HCl extended-release tablets); Sanofi-aventis; For the treatment of of the signs and symptoms of benign prostatic hyperplasia, Approved June 2003
Velcade (bortezomib); Millennium Pharmaceuticals; Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies., Approved May 2003
Drugs Approved in 2002
Eligard (leuprolide acetate); Atrix Laboratories; For the palliative treatment of advanced prostate cancer, Approved January 2002
Eloxatin (oxaliplatin/5-fluorouracil/leucovorin); Sanofi-aventis; For the treatment of colon or rectum carcinomas, Approved August 2002
Faslodex (fulvestrant); AstraZeneca; For the treatment of hormone receptor positive metastatic breast cancer, Approved April 2002
Gleevec (imatinib mesylate); Novartis; For the treatment of gastrointestinal stromal tumors (GISTs), Approved February 2002
Neulasta; Amgen; Treatment to decrease the chance of infection by febrile neutropenia in patients receiving chemotherapy, Approved January 2002
SecreFlo (secretin); Repligen; To aid in the diagnosis of pancreatic dysfunction and gastrinoma, Approved April 2002
Zevalin (ibritumomab tiuxetan); Biogen IDEC; For the treatment of non-Hodgkin's lymphoma, Approved February 2002
Zometa (zoledronic acid); Novartis; For the treatment of multiple myeloma and bone metastases from solid tumors, Approved February 2002
Drugs Approved in 2001
Campath; Berlex Laboratories; Injectable treatment of B-cell chronic lymphocytic leukemia, Approved May 2001
Femara (letrozole); Novartis; First-line treatment of postmenopausal women with locally advanced or metastatic breast cancer, Approved January 2001
Gleevec (imatinib mesylate); Novartis; Oral therapy for the treatment of chronic myeloid leukemia, Approved May 2001
Kytril (granisetron) solution; Roche; For the prevention of nausea and vomiting associated with cancer therapy, Approved June 2001
Trelstar LA (triptorelin pamoate); Debiopharm; Intramuscular injection for the treatment of advanced stage prostate cancer, Approved June 2001
Xeloda; Roche; Oral chemotherapy for the treatment of metastatic colorectal cancer, Approved May 2001
Zometa (zoledronic acid); Novartis; For the treatment of hypercalcemia of malignancy, Approved August 2001
Drugs Approved in 2000
Mylotarg (gemtuzumab ozogamicin); Wyeth; For the treatment of CD33 positive acute myeloid leukemia (AML), Approved May 2000
Trelstar Depot (triptorelin pamoate); Debio Rechereche Pharmaceutique, Target Research Associates; For the palliative treatment of advanced prostate cancer, Approved June 2000
Trisenox (arsenic trioxide); Cell Therapeutics; For the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), Approved September 2000
Viadur (leuprolide acetate implant); Alza; For pain relief in men with advanced prostate cancer, Approved March 2000
Drugs Approved in 1999
Aromasin Tablets; Pharmacia & Upjohn; Exemestane Tablets, 25 mg, October 21, 1999
Busulflex; Orphan Medical; For use in combination for the treatment of leukemia, Approved February 1999
Doxil (doxorubicin HCl liposome injection); Alza; Treatment for ovarian cancer that is refractory to other first-line therapies, Approved June 1999
Ellence; Pharmacia & Upjohn; epirubicin hydrochloride, Approved September 1999
Ethyol (amifostine); U.S. Bioscience, Alza; Treatment for xerostomia (dry mouth) due to radiation, Approved June 1999
Temodar; Schering-Plough; Treatment for refractory anaplastic astrocytoma, Approved August 1999
UVADEX Sterile Solution; Therakos; Treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL), Approved February 1999
Zofran; GlaxoSmithKline; Treatment for the prevention of chemotherapy and radiation-induced nausea, Approved January 1999
Drugs Approved in 1998
Actiq; Anesta Corporation; Treatment for Cancer Pain, Approved November 1998
Anzemet; Hoechst Marion Roussel; Treatment for the prevention of nausea and vomiting associated with chemotherapy and surgery, Approved February 1998
Camptosar; Pharmacia & Upjohn; Treatment for Colon or Rectal Cancer, Approved October 1998
Gemzar (gemcitabine HCL); Eli Lilly; Treatment for Lung Cancer, Approved August 1998
Herceptin; Genentech; Treatment for metastatic breast cancer, Approved October 1998
Inform HER-2/neu breast cancer test; Oncor; Treatment for breast cancer prediction, Approved January 1998
Neupogen; Amgen; Treatment for slow white blood cell recovery following chemotherapy, Approval April 1998
Nolvadex; AstraZeneca; Treatment for Breast Cancer, Approved October 1998
Photofrin; QLT; Treatment for early-stage, microinvasive endobronchial non-small cell lung cancer, Approved January 1998
Proleukin; Chiron; Treatment for metastatic melanoma, Approved January 1998
Sclerosol Intrapleural Aerosol; Bryan Corporation; Treatment for malignant pleural effusions, Approved January 1998
Valstar; Anthra Pharmaceuticals; Treatment for Bladder Cancer, Approved October 1998
Xeloda; Roche; Treatment for advanced breast cancer tumors, Approved April 1998
Zofran; GlaxoSmithKline; Treatment for postoperative vomiting and nausea in adults, Approved April 1998
Drugs Approved in 1997
Anzemet; Hoechst Marion Roussel; Treatment for emesis, Approved September 1997
Bromfenac; Duract, Wyeth-Ayerst Laboratories; Management of acute pain, Approved July 1997
Femara (letrozole); Novartis; Treatment for breast cancer, Approved July 1997
Gliadel Wafer (polifeprosan 20 with carmustine implant); Rhone-Poulenc Rorer, Guilford Pharmaceuticals; Treatment for brain cancer, Approved February 1997
Intron A (interferon alfa-2b, recombinant); Schering-Plough; Treatment for non-Hodgkin's lymphoma, Approved December 1997
Kytril (granisetron) tablets; SmithKline Beecham; Prevention of nausea and vomiting associated with chemotherapy, Approved November 1997
Lupron Depot (leuprolide acetate for depot suspension); TAP Pharmaceuticals; Treatment for prostate cancer, Approved July 1997
Miraluma test; DuPont Merck Pharmaceutical Company; Test for breast cancer, Approved May 1997
Neumega; Genetics Institute; Treatment for thrombocytopenia, Approved November 1997
Quadramet (Samarium Sm 153 Lexidronam Injection); DuPont Merck Pharmaceutical Company; Treatment for pain associated with bone cancer, Approved March 1997
Rituxan; Biogen IDEC, Genentech; Treatment for non-hodgkin's lymphoma, Approved November 1997
Taxol; Bristol-Myers Squibb; Treatment for AIDS-related Kaposi's Sarcoma, Approved August 1997
Drugs Approved in 1996
Anexsia; Mallinckrodt Group; Treatment for chronic pain, Approved August 1996
Aredia (pamidronate disodium for injection); Chiron; Treatment for osteolytic bone metastases of breast cancer, Approved August 1996
Arimidex (anastrozole); AstraZeneca; Treatment for advanced breast cancer in postmenopausal women, Approved January 1996
Campostar; Pharmacia & Upjohn; Treatment for metastatic colorectal cancer, Approved June 1996
CEA-Scan; Immunomedics; Diagnostic imaging product for colorectal cancer, Approved April 1996
Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection); Orphan Medical; Treatment of meningeal leukemia or lymphocytic lymphoma, Approved October 1996
Eulexin (flutamide); Schering-Plough; Treatment for prostate cancer, Approved June 1996
Feridex I.V.; Advanced Magnetics; Contrast agent for magnetic resonance imaging of liver lesions, Approved February 1996
GastroMARK; Advanced Magnetics; Contrast agent for magnetic resonance imaging of the gastrointestinal tract, Approved May 1996
Gemzar (gemcitabine HCL); Eli Lilly; Treatment for pancreatic cancer, Approved May 1996
Hycamtin (topotecan hydrochloride); SmithKline Beecham; Treatment for metastatic ovarian cancer, Approved May 1996
Kadian; Purepac Pharmaceutical; Treatment for chronic moderate to severe pain, Approved July 1996
Leukine (sargramostim); Immunex; Treatment for the replenishment of white blood cells, Approved November 1996
Lupron Depot (leuprolide acetate for depot suspension); Abbott Laboratories; Treatment for advanced prostate cancer, Approved January 1996
Photodynamic Therapy; Sanofi-aventis; Photodynamic therapy device for the treatment of esophageal cancer, Approved January, 1996
Taxotere (Docetaxel); Rhone Poulenc Rorer; Treatment for locally advanced or metastatic breast cancer, Approved May 1996
UltraJect; Mallinckrodt Group; Treatment for chronic pain, Approved August 1996
Visipaque (iodixanol); Nycomed; Diagnostic contrast agent, Approved April 1996
Zoladex (10.8 mg goserelin acetate implant); AstraZeneca; Treatment for advanced prostate cancer, Approved January 1996
Drugs Approved in 1995
Ethyol (amifostine); Alza; Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer, Approved December 8, 1995
Intron A (Interferon alfa-2b, recombinant); Schering-Plough; An adjuvant treatment to surgery in subjects at high risk for systemic recurrence of malignant melanoma, Approved December 1995
Leukine (sargramostim); Immunex; Treatment for mobilizing peripheral blood progenitor cells for use after transplantation., Approved on November 24, 1995
Self-examination breast pad; Inventive Products; Self-examination breast pad, Approved on December 22, 1995
No comments:
Post a Comment